Skip to main content
TipRanks
Go Ultimate75% OFF

DocGo (DCGO) AI Stock Analysis

606 Followers
DCGO

DocGo

(NASDAQ:DCGO)

Select Model
Rating:46Neutral
Price Target:$0.17â–²(0.58% Upside)
Action:reiterated
Date:11/11/26

The score is held down primarily by weak financial performance (significant recent losses and negative TTM cash flow) and bearish technicals (price below all key moving averages with negative MACD). The earnings call provides partial support due to improving operating metrics and an articulated path toward 2027 EBITDA positivity, but near-term guidance still implies losses and cash pressure, limiting the overall rating.

Positive Factors
Revenue RecoveryThe return to year-over-year growth, alongside strong expansion in non-migrant Mobile Health, indicates improving demand across core offerings. A broader mix of transportation, monitoring, phlebotomy, and virtual care can support more durable growth than reliance on migrant-related revenue.
Negative Factors
Persistent Losses and Cash BurnDeep operating losses and negative recent cash generation weaken financial resilience and reduce the company’s ability to fund expansion internally. Even with stable gross margins, continued cost pressure could require additional financing before the planned path to profitability is achieved.

DocGo (DCGO) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%DCGO-83.24%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$16.99M
Dividend Yield
―
Average Volume (3M)
721.43K
Price to Earnings (P/E)
-0.1
Beta (1Y)
1.67
Revenue Growth
-19.22%
EPS Growth
-254.04%
Country
US
Employees
3,568
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

DocGo Business Overview & Revenue Model

Company Description

DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom. Their transportation portfolio includes critical emer...

DocGo Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:-31.87%|Next Earnings Date:Mar 15, 2027
Earnings Call SentimentPositive

The call was broadly constructive, with substantial sequential improvement in adjusted EBITDA, gross margin, SG&A, transportation revenue, non-migrant Mobile Health growth, and operating efficiency. Management also outlined a path toward positive adjusted EBITDA in 2027 and continued progress on portfolio optimization. However, the company remains loss-making, reduced 2026 revenue guidance, reported declining cash, faced lower Mobile Health margins and elevated fuel costs, and is managing a CEO transition. Overall, the number and significance of the operational improvements outweighed the disclosed challenges.

Positive Updates

Revenue Returned to Year-Over-Year Growth
Third-quarter revenue was $73.4 million, up 4% from $70.8 million in the third quarter of 2025. This was DocGo's first year-over-year revenue increase since the second quarter of 2023. Excluding $8.4 million of migrant-related revenue in the 2025 period, revenue increased 18% year over year; excluding both migrant-related revenue and SteadyMD revenue, revenue still increased approximately 5%.

Negative Updates

Full-Year Revenue Guidance Reduced
DocGo revised 2026 revenue guidance to approximately $300 million from the previous range of $305 million-$310 million. Management attributed the revision to restructuring or discontinuing unprofitable business lines, with additional reductions in SteadyMD, Care in the Home, and selected contracts and markets.

Company Guidance

DocGo reaffirmed full year 2026 adjusted EBITDA guidance of a loss of $17 million-$22 million and revised revenue guidance to approximately $300 million, excluding any revenue from Hicuity Health; fourth-quarter revenue is expected to be somewhere in the $77 million, $78 million range or something like that, which management said looks very achievable. Medical transportation is expected to contribute about $205 million or so to $210 million, remote patient monitoring $16 million-$17 million, SteadyMD between $30 million and $35 million, mobile phlebotomy between $5 million and $6 million, clinical staffing about $14 million, $15 million, and Care in the Home probably $7 million or $8 million, maybe even as much as $9 million. For 2027, the company specifically did not issue guidance, but expects some solid revenue gains year-over-year, medical transportation growth at a high single-digit level, a little bit more moderated growth in Care in the Home, and some positive adjusted EBITDA for the full year; management also said positive operating cash flow might occur in Q1 or maybe even Q2.

DocGo Financial Statement Overview

Summary

Overall fundamentals are pressured by a sharp swing to significant losses (2025 and TTM) and negative EBITDA, despite relatively steady gross margins in the low-to-mid 30% range. The balance sheet leverage appears manageable (modest debt-to-equity), but cash flow has been volatile with negative operating and free cash flow in the latest TTM, increasing near-term funding and execution risk.

Income Statement

24Negative

Balance Sheet

56Neutral

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue297.34M322.20M616.56M624.29M440.52M318.72M
Gross Profit95.12M98.76M213.57M195.38M154.72M109.75M
EBITDA2.64T-170.82M45.56M32.73M33.35M27.63M
Net Income-181.25M-182.40M19.99M6.86M34.58M23.74M
Balance Sheet
Total Assets173.90M217.10M455.62M490.45M393.28M309.60M
Cash, Cash Equivalents and Short-Term Investments19.11M51.02M89.24M59.29M157.34M175.54M
Total Debt24.64M29.18M57.19M46.50M19.91M16.51M
Total Liabilities94.92M91.23M140.44M185.28M114.35M82.55M
Stockholders Equity105.08M144.01M320.92M300.79M273.23M219.58M
Cash Flow
Free Cash Flow-30.99M27.02M64.50M-74.35M23.37M-8.60M
Operating Cash Flow-27.99M34.45M70.34M-64.22M28.87M-1.95M
Investing Cash Flow-16.47M-39.08M-10.87M-29.88M-38.45M-8.59M
Financing Cash Flow-9.09M-50.82M-24.15M1.12M-6.18M155.21M

DocGo Technical Analysis

Technical Analysis SentimentNegative
Last Price0.17

Price Trends

50DMA0.30Negative
100DMA0.43Negative
200DMA0.53Negative

Market Momentum

MACD-0.03Positive
RSI29.60Positive
STOCH4.26Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCGO, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.30, and below the 200-day MA of 0.53, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 29.60 is Positive, neither overbought nor oversold. The STOCH value of 4.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCGO.

DocGo Risk Analysis

DocGo disclosed 72 risk factors in its most recent earnings report. DocGo reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Impairments of the carrying value of DocGo's goodwill and other intangible assets have adversely affected its financial condition and results of operations and could again in the future.Q4, 2025
2.DocGo's current liquidity could raise substantial doubt about its ability to continue as a going concern, which may materially and adversely affect its business, financial condition, results of operations and prospects.Q4, 2025
3.DocGo has entered in the past, and may enter in the future, joint ventures and other contractual relationships with healthcare provider partners and other strategic partners that may be novel and subject to certain commercial and other risks, and DocGo cannot guarantee that such partnerships will be operationally or financially successful.Q4, 2024

DocGo Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DCGO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ADUSADUS83Outperform$2.26B20.189.81%―11.53%27.72%
VMDVMD75Outperform$326.26M21.1410.78%―21.81%17.67%
AVAHAVAH65Neutral$2.34B7.28115.53%―16.84%280.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
DCGODCGO46Neutral$16.99M-0.09-144.87%―-19.22%-254.04%
MNDRMNDR43Neutral$1.13M-0.04-27.32%―4.47%92.03%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DCGOADUSVMDAVAHEUDAMNDRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DCGO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DCGODocGo, Inc.0.17-0.80-82.33%
ADUSAddus HomeCare Corporation121.078.377.43%
VMDViemed Healthcare US8.611.9529.28%
AVAHAveanna Healthcare Holdings Inc10.701.9622.43%
EUDAEuda Health Holdings Limited17.37-39.23-69.31%
MNDRMobile-health Network Solutions Class A0.95-27.55-96.68%

DocGo Corporate Events

Executive/Board Changes

DocGo Announces CEO Transition and Separation Agreement

Neutral
Nov 13, 2026

DocGo Inc. said on November 13, 2026, that it had entered into a Transition Services and Separation Agreement with CEO Lee Bienstock as it searches for a successor before his employment agreement expires on December 31, 2026. The agreement provides f...

Business Operations and StrategyPrivate Placements and Financing

DocGo Secures New Credit Facility and Warrant Financing

Neutral
Oct 5, 2026

On October 1, 2026, DocGo and subsidiaries Hicuity and Ambulnz entered into an amended and restated credit agreement and guaranty that refinances existing debt and adds new term loan facilities totaling up to $102 million, maturing on December 6, 202...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026